---
title: "Weekly Recap | Monster Beverage -3.42%, earnings beat but regulatory pressure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304723299.md"
description: "Monster Beverage (MNST) fell 3.42% this week to $45.72, underperforming the S&P 500 by roughly 0.74 percentage points. The stock climbed through Monday to Wednesday, hit a weekly high of $49.5 on Thursday, then reversed sharply on Friday to a low of $43.933 before closing at $45.72. The weekly range was 11.65%, and average daily volume of about 13.1m shares ran 40.6% above the median, a clear step-up in activity."
datetime: "2026-11-07T08:23:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304723299.md)
  - [en](https://longbridge.com/en/news/304723299.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304723299.md)
generator: "portal-rs"
---

# Weekly Recap | Monster Beverage -3.42%, earnings beat but regulatory pressure

## The Week

Monster Beverage (MNST) fell 3.42% this week to $45.72, underperforming the S&P 500 by roughly 0.74 percentage points. The stock climbed through Monday to Wednesday, hit a weekly high of $49.5 on Thursday, then reversed sharply on Friday to a low of $43.933 before closing at $45.72. The weekly range was 11.65%, and average daily volume of about 13.1m shares ran 40.6% above the median, a clear step-up in activity.

## Key Events

The week was dominated by Friday’s Q3 results and an escalating regulatory story in India. Net sales rose 17% year on year to $2.56bn and net profit rose 8% to $568.43m, beating sales estimates, but margin pressure sent the stock down nearly 6% in after-hours trade. India’s food safety regulator said PepsiCo and Monster misled consumers with energy-drink labelling and argued the companies’ legal challenges should be dismissed. The story built from Wednesday and pressed the stock through Friday. Institutional holdings updates and a 10-Q filing also landed, but the market’s attention stayed on earnings and regulation.

## Analyst Ratings

Among 26 covering analysts, 11 rate it buy, 3 overweight, 10 hold, 1 underweight and 1 has no opinion; no one rates it sell. The stock ranks first among 16 names in its industry. The consensus rating is buy, and the consensus target of $49.93 sits about 9.2% above the spot price. Target prices range from $37 to $57, reflecting a wide dispersion of views.

## The Week Ahead

The main macro event is Tuesday’s US CPI report, with core CPI seen at 2.8% versus 2.6% previously. That print will shape how markets price the Fed’s path. On the company side there is nothing new scheduled in the coming week; the next major date is the FY2026 annual results after the close on 25 February 2027, where the market expects EPS of $1.1366 on revenue of $9.758bn.

## In Short

This week leaves a tension: sales beat expectations and the street’s consensus remains buy with targets roughly 9% above spot, but India-related regulatory risk is now live, margin pressure is visible, and Friday’s sell-off was sharp. What matters next is whether the regulatory story escalates, whether costs keep squeezing margins, and how Tuesday’s CPI shifts broad risk appetite. That is the setup to monitor.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [MNST.US](https://longbridge.com/en/quote/MNST.US.md)

## Related News & Research

- [Is Monster Beverage (MNST) A Bargain Following Strong Earnings Growth?](https://longbridge.com/en/news/305517740.md)
- [Wolfe Research initiates coverage of Monster Beverage at Outperform](https://longbridge.com/en/news/305956257.md)
- [BUZZ-Street View: Nvidia's AI story intact despite uncertainty at top](https://longbridge.com/en/news/305945171.md)
- [Sandisk (SNDK) Stock Could Be 42% Below Fair Value Following Data Center Regulation Fears](https://longbridge.com/en/news/305917622.md)
- [INSTANT VIEW-Nvidia earnings beat estimates; attention turns to call](https://longbridge.com/en/news/305875718.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**